Rapid Novor Inc

10/06/2026

We are seeking an energetic & enthusiastic Business Operations Assistant to join our innovative team. This hands-on role will support the Business Operations team with coordinating employee events & activities, while also handling a broad range of office supply & support tasks. This is a part-time role with a regular schedule of twenty (20) hours per week.

https://workforcenow.adp.com/mascsr/default/mdf/recruitment/recruitment.html?cid=605d5942-e530-49b1-b1a6-e4b1db591443&ccId=19000101_000001&jobId=575948&lang=en_CA

07/30/2026

Today's the last day to visit us at the 2026 exhibition!

Stop by booth #2546 and say hi to Jennifer, Kyle, Mingjie, Lindsey, and Natasha!

📍 Anaheim Convention Center | Anaheim, CA

07/22/2026

Would you move this antibody candidate forward?

At first glance, this antibody looks like a good binder. But a closer look at the sensorgram reveals subtle features that could change your mind.

This is where expertise matters.

In our upcoming webinar, Rapid Novor's SPR expert Marko Jovic shares lessons learned from hundreds of antibody interaction studies, highlighting the recurring blind spots that can influence antibody validation, candidate selection, and downstream development. You'll also see that when SPR reveals something unexpected is happening, HDX-MS can help explain why, making the two techniques a powerful combination for antibody characterization.

🔎 𝗪𝗲𝗯𝗶𝗻𝗮𝗿: The Top 6 Blind Spots of Antibody Discovery and Development
📅 𝗗𝗮𝘁𝗲: Tuesday, July 29, 2026
🕑 𝗧𝗶𝗺𝗲: 2:00-2:30 PM EST

We'll discuss:
• What most kinetic screens get wrong.
• The most overlooked epitope mapping scenarios.
• The “unknown” unknowns - what the synergy between HDX-MS and SPR reveal about advanced antibody biochemistry.

👉 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://hubs.li/Q04qjqXW0

07/16/2026

Ever wondered what happens behind the scenes at Canada’s largest privately-funded mass spec facility?

Step inside to see where we’ve sequenced over 10,000 antibodies using cutting-edge mass spectrometry and proprietary sequencing technology.

Take a behind-the-scenes tour below, and don’t forget to tell us what you’ll sequence next! 👇

07/15/2026

🚨 We’re heading to ADLM2026 in Anaheim, CA!

From July 26–30, stop by booth 2546 to meet Jennifer, Kyle, Lindsey, Natasha, and Mingjie and learn how we're converting polyclonal antibodies into recombinant polyclonals, with consistency and reproducibility in mind. Discover how SPR and HDX-MS provide a more complete understanding of antibody binding interactions

📍 Don’t miss our poster:
“From Polyclonal to Recombinant: A Proteomics Workflow for Anti-Idiotype Antibody Development”
📅 Wednesday, July 29 | Poster B-149

07/10/2026

🎥 Missed our webinar on anti-idiotype antibody discovery? Don’t worry, we recorded it just for you.

Check out this short clip of Thierry Le Bihan explaining the advantages of a protein-first approach in antibody discovery compared to other approaches.

Then, watch the full recording to see how the antibodies discovered using our REpAb platform compare to their commercial counterparts.

👉 Access the full webinar here:
https://hubs.li/Q04pc4Gx0

In this webinar, you will learn: How integrated protein sequencing, SPR, and HDX-MS workflows can accelerate anti-idiotype antibody discovery pipelines. Strategies to discover all three functional anti-idiotype antibody subtypes with strong functional performance and low cross-reactivity to endogeno...

07/09/2026

💡What can we learn from hundreds of successful antibody characterization campaigns?

Join Rapid Novor’s SPR and HDX-MS experts Marko Jovic and Dominic Narang for a deep dive into the 𝘁𝗼𝗽 𝟲 𝗼𝘃𝗲𝗿𝗹𝗼𝗼𝗸𝗲𝗱 𝗳𝗮𝗰𝘁𝗼𝗿𝘀 𝗶𝗻 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝗼𝗻 𝘀𝘁𝘂𝗱𝗶𝗲𝘀 𝘁𝗵𝗮𝘁 𝗰𝗮𝗻 𝗰𝗼𝗻𝘁𝗿𝗶𝗯𝘂𝘁𝗲 𝘁𝗼 𝗳𝗮𝗶𝗹𝗲𝗱 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀 𝗶𝗻 𝗹𝗮𝘁𝗲𝗿 𝘀𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁.

In this interactive conversation, we will be bringing actionable insights into how you can derisk your next antibody project.

Marko and Dominic will share practical insights into:
• Commonly missed considerations that impact antibody validation and candidate selection.
• How a deeper understanding of antibody biochemistry can help generate more reliable characterization data.
• Experimental design and optimization strategies for antibody kinetics and epitope mapping.

This webinar is the first in a planned three-part series exploring the intersection of antibody discovery, characterization, and therapeutic development. Stay tuned as we reveal the special guests and real-world therapeutic case studies featured in upcoming sessions.

🧬 𝗪𝗲𝗯𝗶𝗻𝗮𝗿: The Top 6 Blind Spots of Antibody Discovery and Development
📅 𝗗𝗮𝘁𝗲: Tuesday, July 29, 2026
🕑 𝗧𝗶𝗺𝗲: 2:00 PM EST

👇 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 𝘁𝗼 𝘀𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁!
https://hubs.li/Q04p2prk0

In this webinar, you will learn: Six frequently missed observations with critical impacts on antibody validation, hit selection and candidate characterization efforts. Antibody biochemistry tips for design of SPR, and mass spectrometry-based epitope mapping workflows.

07/08/2026

𝗖𝗮𝗻𝗰𝗲𝗿 𝗰𝗲𝗹𝗹𝘀 𝘀𝗲𝗻𝗱 𝘀𝗶𝗴𝗻𝗮𝗹𝘀. 𝗖𝗮𝗻 𝘄𝗲 𝗳𝗶𝗻𝗱 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝗶𝗲𝘀 𝘁𝗵𝗮𝘁 𝘀𝗶𝗹𝗲𝗻𝗰𝗲 𝘁𝗵𝗲𝗺?

New research from Ben-Shalom, Freund and colleagues reveals the discovery of antibodies that can disrupt pro-survival signaling in melanoma cells, exposing a new therapeutic vulnerability.

Melanoma cells release melanosomes, specialized extracellular vesicles that normally transport melanin, but can be repurposed by cancer cells to deliver pro-tumorigenic signals to surrounding cells in the tumor microenvironment (i.e. a paracrine mechanism). The authors in this study demonstrated for the first time that melanosomes 𝘢𝘭𝘴𝘰 support the growth and survival of the same melanoma cells that produce them (i.e. an autocrine mechanism).

𝗞𝗲𝘆 𝗳𝗶𝗻𝗱𝗶𝗻𝗴𝘀:
• Immunization with melanosomes generated antibodies against extracellular HSP70, located on the melanosome vesicle surface. These antibodies acted similarly to neutralizing antibodies targeting viral antigens, blocking HSP70-mediated signaling and reducing melanoma cell survival.
• These anti-HSP70 antibodies inhibited melanoma growth 𝘪𝘯𝘥𝘦𝘱𝘦𝘯𝘥𝘦𝘯𝘵𝘭𝘺 of additional immune effector cells (like NK cells).
• Anti-HSP70 antibodies inhibited melanoma growth in mouse models, leading to delayed tumor development and improved survival.
• In metastatic melanoma patients receiving immune checkpoint therapy, stronger anti-HSP70 antibody responses were associated with complete responses, highlighting a potential link between antibody immunity and treatment outcomes.

This work positions melanosomes as a promising platform for therapeutic discovery and identifies extracellular HSP70 as a potential target for antibody-based melanoma therapies.

📄𝗖𝗵𝗲𝗰𝗸 𝗼𝘂𝘁 𝘁𝗵𝗲 𝗽𝗮𝗽𝗲𝗿 𝗵𝗲𝗿𝗲: https://hubs.li/Q04nYgw10

07/07/2026

Every assay tells part of the story. The best lead selection decisions come from putting the pieces together.

👉See how SPR and HDX-MS work together to provide a more complete picture of antibody–antigen interactions.

What complementary techniques does your team rely on for lead candidate selection?

06/12/2026

Some binders never get a second chance.

Early antibody selection decisions determine which candidates move forward and which are left behind, but not all screening methods give you all the information you need to make the best decision moving forward.

Our SPR Kinetic Screening using the Biacore 1K is designed to uncover the interactions that less sensitive approaches can miss.

Because the best hit might have been the one that was left behind.